TransThera Biosciences Co. Ltd
http://www.transtherabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TransThera Biosciences Co. Ltd
Oncology, Cell Therapy Developers Bag $175m In China
Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.
Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Nanjing Transtherabio Sciences Co. Ltd.
- Nanjing TransThera Biosciences Co. Ltd.